28 December 2021 | News
Collaborates with WuXi Biologics for development and manufacturing of Anti-PD-L1/CD47 bispecific antibody
image credit- shutterstock
ImmuneOncia Therapeutics, Inc., a clinical-stage, immuno-oncology startup in South Korea, has announced that a Memorandum of Understanding (MOU) has been signed with WuXi Biologics to form a strategic partnership in the development and manufacturing of IOH-001, ImmuneOncia's therapeutic bispecific antibody targeting PD-L1 and CD47.
Within the partnership, ImmuneOncia will have access to WuXi Biologics' integrated services in cell line development, cell culture development, biologics manufacturing and bioassay development. WuXi Biologics will support ImmuneOncia on the whole CMC studies of IOH-001 for Investigational New Drug (IND) application.
Heung Tae Kim, CEO of ImmuneOncia, commented, "WuXi Biologics' comprehensive capabilities on bispecifics development and manufacturing will enable us to focus on realizing the therapeutic potential of IOH-001. More importantly, access to WuXi Biologics' world-leading technologies will help ensuring its efficacious and sustainable development. We look forward to expanding collaboration in the future to bring more innovative biologics for patients in South Korea.”